The Everett Clinic, Part of Optum, Everett, WA.
Office of Research and Development, Veterans Health Administration, Washington, DC.
Crit Care Med. 2020 Nov;48(11):1680-1689. doi: 10.1097/CCM.0000000000004594.
We explore ways to reduce errors in laboratory diagnosis of severe acute respiratory syndrome-coronavirus 2 infection by considering preanalytic, analytic, and postanalytic sources. To address preanalytic challenges, we first consider alternative anatomic sites for specimen collection, then discuss self-collection, alternative sampling devices, and transport media. Strengths and limitations of various analytic test systems are considered in the context of postanalytic challenges associated with making test results meaningful, specifically considering the complex relationship between "positive" test results and reproduction and shedding of intact virus. Finally, we provide recommendations regarding healthcare worker surveillance and release of patients with coronavirus disease 2019 from isolation.
Material was derived from a Webinar available to the public, manufacturer's websites, U.S. Food and Drug Administration, and Centers for Disease Control and Prevention websites and from both peer-reviewed papers identified by PubMed search and nonpeer-reviewed papers posted on Biorxiv and Medrxiv. Unpublished data came from the Washington State Department of Health.
We included studies that compared diagnostic performance strategies without introducing bias due to use of an imperfect gold standard. Case series and case reports were included as necessary to illuminate the significance of results.
Data were extracted manually.
Sensitivity, specificity, and CIs were computed from article data using a composite reference standard. Nucleic acid-based tests were assumed to perform at 100% specificity.
Although sputum and bronchoalveolar lavage samples provide the highest diagnostic sensitivity for severe acute respiratory syndrome-coronavirus 2, nasopharyngeal, mid turbinate, and nasal specimens are suitable in most cases and require less use of personal protective equipment. When desired sampling materials are unavailable, alternatives may be substituted with no loss of performance. Both reverse transcriptase polymerase chain reaction tests and rapid nucleic acid-based tests offer good performance in most circumstances. Testing is not required to release most patients from isolation.
通过考虑分析前、分析中和分析后三个环节的来源,探索降低严重急性呼吸综合征冠状病毒 2 感染实验室诊断错误的方法。为了解决分析前的挑战,我们首先考虑了标本采集的替代解剖部位,然后讨论了自我采集、替代采样设备和运输介质。在与使检验结果有意义相关的分析后挑战的背景下,考虑了各种分析检测系统的优势和局限性,特别是考虑到“阳性”检验结果与完整病毒的复制和脱落之间的复杂关系。最后,我们就医护人员监测和 2019 冠状病毒病患者解除隔离问题提供了建议。
资料来源于公开的网络研讨会、制造商网站、美国食品和药物管理局以及疾病控制和预防中心网站,以及通过 PubMed 搜索确定的同行评议论文和发表在 Biorxiv 和 Medrxiv 的非同行评议论文。未发表的数据来自华盛顿州卫生部。
我们纳入了比较诊断性能策略的研究,这些研究没有因使用不完美的金标准而引入偏倚。必要时纳入了病例系列和病例报告,以阐明结果的意义。
数据通过人工提取。
使用综合参考标准从文章数据中计算出敏感性、特异性和置信区间。假设基于核酸的检测具有 100%的特异性。
虽然痰和支气管肺泡灌洗液样本对严重急性呼吸综合征冠状病毒 2 的诊断敏感性最高,但在大多数情况下,鼻咽、中鼻甲和鼻标本都适用,且需要较少使用个人防护设备。在所需采样材料不可用时,可以用替代品替代,而不会影响性能。逆转录酶聚合酶链反应检测和快速核酸检测在大多数情况下都有良好的性能。大多数情况下,无需检测即可将大多数患者解除隔离。